-
JAMA: Effects of postmenopausal hormone intervention on breast cancer morbidity and mortality in women.
Time of Update: 2020-08-06
Researchers recently looked at the effects of menopausal hormone therapy on breast cancer morbidity and mortality. this long-term follow-up controlled randomized clinical trial involving 27,347 postm
-
Clin Cancer Res: Ganetespib in combination with permeitus ssp. platinum to treat malignant pleural mesothelioma.
Time of Update: 2020-08-06
treatment with the highest tolerable dose of Ganetespib, 10 (56%) of the 18 patients received partial remission, 15 (83%) were under control, with a median PFS of 6.3 months.
-
Enter the field of breast cancer! Mercadon Keytruda (Corrida) 2 applications were accepted by the FDA for treatment of triple-negative breast cancer (TNBC)!
Time of Update: 2020-08-06
the FDA will conduct a standard review of another sBLA that seeks approval for Keytruda for use in high-risk early TNBC patients, specifically for the use of Keytruda combined chemotherapy for new preoperative complementary therapy, and then as a single drug for postoperative assisted therapy.
-
Medicine: Abortion increases the risk of breast cancer?! NO!
Time of Update: 2020-08-06
comprehensive risk ratio (RR) shows that there is no significant association between abortion and breast cancer in women who are infertile (RR-1.023, 95% CI-0.938-1.117; Z-0.51, P-607).
in general, evidence based on epidemiological studies suggests no association between miscarriage and breast cancer risk in infertile women.
-
Clin Cancer Res: CMV-specific T cells treat glioblastoma.
Time of Update: 2020-08-06
first collected high-function autologous multi-clone CMV pp65-specific T cells in patients with glioblastoma, amplification in vitro, and transplanted back into the patient after 3 weeks of demotina (100 mg/m2) treatment.
screened 65 patients, 41 cytomegalovirus seropositives, 25 were cetic cell isolation, and 20 completed at least one course of treatment.
-
JAMA Oncol: Superprogressia in nSCLC immunotherapy for advanced non-small cell lung cancer.
Time of Update: 2020-08-06
a study published in JAMA Oncology, , to assess the accuracy of each previous HPD definition to determine the incidence of HPD in patients with advanced non-small cell lung cancer (NSCLC) under different HPD definitions and the correlation with adverse outcomes of immunocheckpoint inhibitors (ICI) treatments, and to provide an optimized, consistent and consistent definition of HPD on top of all previous HPD criteria.
-
Am J Clin Nutr: Effects of preoperative intravenous omega-3 fatty acids in colon cancer patients.
Time of Update: 2020-08-06
44 patients who underwent selective colonectomy with non-metastatic cancer, were randomly assigned to two intravenous n-3 PUFA or physiological saline controls on the eve of surgery and on the morning after surgery.
-
CAR-T Killer! FDA approved CD19 target new Fc optimized immune-enhanced antibody Monjuvi, the treatment of B-cell tumors is strong!
Time of Update: 2020-08-06
!--webeditor: "page title"--// Morpho Sys and Incyte recently jointly announced that the U.S. Food and Drug Administration (FDA) has approved Monjuvi (tafasitamab-cxix, MOR 208), the combination of lenalidomide, for the treatment of recurrent or refractable diffuse large B-cell lymphoma (r/r DLBCL) patients who are not suitable for an autonomous stem cell transplant (ASCT), including DLBCL derived from low-level lymphoma.
-
Nat Commun: HER2-positive breast cancer changes during and after double HER2 blocking.
Time of Update: 2020-08-06
The HER2 enrichment (HER2-E) subtype in HER2-plus breast cancer is highly dependent on the HER2 pathway.
in general, the results support the use of maintenance anti-HER2 therapy and the use of CDK4/6 inhibition for subtype switching.
-
Summary: Recent advances in immunotherapy based on autologous tumor-immersed lymphocytes (TIL).
Time of Update: 2020-08-06
Therefore, after PD-1 treatment, TILs therapy still has the ability to achieve long-lasting remission of advanced metastatic non-small cell lung cancer, which is very remarkable, i hope this therapy can increase research, early approval to market, for the life of advanced patients continue to survive!
-
Roche PD-L1 monoanti-Tecentriq joint targeted therapy: FDA approved for treatment of advanced melanoma.
Time of Update: 2020-08-06
Roche announced that the U.S. Food and Drug Administration (FDA) has approved its PD-L1 monoantitic Tecentriq joint MEK inhibitor Cotellic (cobimetinib) and BRAF inhibitor Zelmurabraf for the treatment of patients with braF V600 mutation-positive advanced melanoma.
-
Kidney cancer "immune and targeted" first-line treatment! Pfizer and Merck Bavencio and Inlyta combination therapy have been approved by NICE IN!
Time of Update: 2020-08-06
Professor Amit Bahl, medical oncologist who specializes in renal cell carcinoma at the , said: "This positive recommendation from NICE provides an effective and well-tolerated treatment for patients with advanced kidney cancer, and the results from the random phase III trial confirm the benefits of Bavencio-Inlyta combination therapy in terms of progression-free survival and objective remission rates.
-
Cancer Discov: A new treatment for three-negative breast cancer- BBOX1 inhibitors.
Time of Update: 2020-08-06
injected mice with modified three-negative breast cancer cells that directly shut down the BBOX1 gene, preventing the growth of primary tumors.
, Dr. Zhang Qing believes that BBOX1 inhibitors, including Mildronate, could eventually become the target therapy that patients with triple-negative breast cancer have been waiting for.
-
Clinical I/II study of VB-111 gene therapy recurrence GBM.
Time of Update: 2020-08-06
Research Methods the study included 72 patients with relapsed GBM, divided into 4 groups: 119 sub-treatment groups (SubT), VB-111 virus with applied doses below 1x1013; VB-111 pre-treatment of the combined beva monobsalystreatment group, every 56 days to 1 VB-111, after the progressofy of the disease to continue VB-111, and combined with every 2 weeks 1 times bevelav it and 410 cases of non-pre-treatment combination group, every 28 days 1 vb-111 combined every 2 weeks 1 time Beva syntod.
-
Rozlytrek (entrectinib) for the treatment of NTRK gene fusion of solid tumors: has been approved by the European Union.
Time of Update: 2020-08-06
the European Commission also approved Rozlytrek for the treatment of ROS1-positive, advanced non-small cell lung cancer (NSCLC) patients previously not treated with ROS1 inhibitors.
Rozlytrek was first approved in Japan last year for the treatment of late-stage recurrent solid tumors with NTRK gene fusion.
-
mRNA Cancer Vaccine and Immune Checkpoint Suppression! BioNTech partnered with Regenerative Element to develop a BNT111/Libtayo combination to treat melanoma!
Time of Update: 2020-08-06
, the company recently announced a strategic partnership with Regeneron to conduct a clinical trial of a mRNA immunotherapy, BNT111 FixVac, in combination with the anti-PD-1 therapy Libtayo (cemiplimab) to treat melanoma.
-
The administration is only 3-5 minutes! Johnson and Johnson Darzalex (megacopic ®) subcutaneous preparation myeloma Phase III Clinical Success: Significantly Prolonged Progression Survival!
Time of Update: 2020-08-06
(JNJ) and the European Myeloma Network (EMN) have announced the release of myeloma drug Darzalex (Mega®, generic name: dardar Positive results from the study of APOLLO (MMY3013, NCT03180736) of the subcutaneous (SC) preparation for the treatment of relapsed or refractive multiple myeloma (R/R MM) PHASE III APOLLO (MMY3013, NCT03180736).
-
Melanoma "immune-targeted" therapy! Roche Tecentriq three-drug program approved by the U.S. FDA to treat BRAF V600-positive patients!
Time of Update: 2020-08-06
July 31, 2020 // Roche has announced that the U.S. Food and Drug Administration (FDA) has approved the anti-PD-L1 therapy Tecentriq (atezolizumab) joint targeting of the anti-cancer drugs Cotellic (cobimetinib) and Zelboraf (vemurafenib) for the treatment of patients with advanced melanoma with the BRAF V600-positive mutation.
-
Dev Cell: Use genealogical tracing techniques to capture the EMT process in tumor metastasis in the body.
Time of Update: 2020-08-06
In this research project, Zhou Bin research team based on the double homologous recombination system to create induced seamless genealogy tracing technology, with spontaneous breast cancer tumor model mouse MMTV-PyMT as the research object, using Kit-CreER to mark the mouse breast cavity epithelial cells The gene used to track EMT was built to tap into mice N-Cad-LSL-Dre and Vim-LSL-Dre, using dual homologous reported gene mice NR1 to track both the occurring and the absence of EMT breast tumor cells.
-
Lancet Oncology: There are so many microorganisms in the human body, what are their effects on the occurrence and treatment of cancer?
Time of Update: 2020-08-06
one of the studies, from the MD Anderson Cancer Center team, showed significant differences in the diversity and composition of the intestinal microbiome between patients who were treated with melanoma who were treated with anti-PD-1 immunotherapy.
